Agendia
I-SPY 2.2 Study IDs Early Breast Cancer Patients Who Benefit From Pre-Surgery Dato-DXd, Imfinzi
Premium
The adaptive basket trial, which matches patients to treatments based on complex biomarker signatures, could help shape future Phase III clinical trials.
Agendia Gets CE-IVDR Certification for MammaPrint, BluePrint FFPE Breast Cancer Tests
The assays are versions of Agendia’s MammaPrint and BluePrint tests that use formalin-fixed paraffin-embedded tissue samples instead of fresh tissue.
UK's NICE Expands Tumor Profiling Recommendations for Guiding Adjuvant Chemo in Early Breast Cancer
Previously, NICE recommended EndoPredict, Prosigna, and Oncotype DX for node-negative breast cancer only, but the new guidance includes lymph node-positive disease.
In Brief This Week: Syros Pharmaceuticals, AdrenoMed, Telo Genomics, Aspira Women’s Health
News items for the week of April 8, 2024.
Agendia's ImPrint Headed for Prospective Validation as Tool for Guiding Breast Cancer Immunotherapy
Premium
Retrospective data in two breast cancer subtypes have shown the test's ability to identify responders to neoadjuvant immunotherapy with chemo.
Oct 11, 2023
Jun 4, 2023
Jun 12, 2020